Novo Nordisk A/S – Page 4

Buried in Wegovy Costs, North Carolina Will Stop Paying for Obesity Drugs

Starting April 1, state employees in North Carolina will no longer have insurance coverage for costly weight-loss medications like Wegovy and Zepbound.

By Rebecca Robbins

Drugs (Pharmaceuticals) Eli Lilly and Company Health Insurance and Managed Care Novo Nordisk A/S Obesity Ozempic (Drug) Prices (Fares, Fees and Rates) Semaglutide (Drug) Tirzepatide

How Much Do Ozempic and Wegovy Cost? Not What You Think.

Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.

By Gina Kolata

Health Insurance and Managed Care Medicare Novo Nordisk A/S Obesity Semaglutide (Drug) Suits and Litigation (Civil)

Lawsuit Challenges Insurance Restrictions on Weight Loss Drugs Like Wegovy

Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy.

By Rebecca Robbins

Denmark Diabetes Drugs (Pharmaceuticals) Economic Conditions and Trends Gross Domestic Product Novo Nordisk A/S Ozempic (Drug) Semaglutide (Drug) Wegovy

Novo Nordisk’s Ozempic and Wegovy Reshape Denmark’s Economy

Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of the country’s economic growth.

By Eshe Nelson